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The oral delivery of protein and peptide drugs is limited
by their proteolytic degradation and the poor absorption
across the intestinal epithelia. In this work, we exposed a
phage library of small bicyclic peptides (<1.5 kDa) to a
pancreatic extract of proteases prior to affinity selection
to enrich binders with higher stability in the intestinal en-
vironment. Panning with the therapeutic target plasma
kallikrein yielded potent inhibitors (Kis between 5.6 and
336 nM) wherein bicyclic peptides isolated with proteolyt-
ic pressure were more stable. A proline residue found in a
specific position of several resistant bicyclic peptides
proved to be a ‘protective mark’, rendering the bicyclic
peptides resistant to significantly higher concentrations of
intestinal proteases while retaining essentially their in-
hibitory activity.
Keywords: bicyclic peptide/phage display/plasma kallikrein/
proteolytic phage display/proteolytic stability
Introduction
Protein and peptide therapeutics have excellent properties
such as high potency and selectivity but generally require
parenteral application which is not convenient, particularly in
the treatment of chronic diseases. The oral delivery of thera-
peutic peptide and protein drugs has ever since been a chal-
lenge as the digestive tract does not differentiate between
therapeutic and non-therapeutic polypeptides and therefore
protein and peptide drugs are digested as the food protein are
(Mahato et al., 2003). As a result of this proteolytic degrad-
ation and the poor absorption across the intestinal epithelia,
the oral bioavailability of most protein and peptide drugs is
significantly ,1% (Zhou and Li Wan Po, 1991). Toward the
generation of orally available biologics, a number of engin-
eering and formulation strategies have been applied, of
which some have led to the establishment of oral peptide
treatments (Morishita and Peppas, 2006; Antosova et al.,
2009).
One step toward the development of more orally available
protein and peptide drugs consists in increasing the proteolyt-
ic stability of this class of therapeutics. Various approaches
have been used to achieve this goal including chemical
modification of peptide termini, replacement of amino acid
side chains or amide bonds, inversion of configurations and
peptide cyclization (Zhou and Li Wan Po, 1991). Recently, a
highly stable thrombin inhibitor was engineered by inserting
a binding region into a proteolytically stable knottin scaffold
(Getz et al., 2011). Formulation excipients containing
enzyme inhibitors or pH-lowering buffer, both leading to di-
gestive enzyme inactivation, have been developed (Morishita
and Peppas, 2006). Coating of the protein or peptide drug
using various polymers, liposomes or nanoparticles also con-
tributed to increased resistance to proteolytic degradation
(Morishita and Peppas, 2006). For example, coating insulin
with amphiphilic oligomers, protecting this drug from the
action of digestive enzymes as well as facilitating its absorp-
tion through the intestinal epithelia, increased its oral bio-
availability up to 5% (Kipnes et al., 2003; Morishita et al.,
2006). Considering the typically high potencies of protein
and peptide drugs, a bioavailability even below 1% may be
sufficient to achieve therapeutic effects.
Here, we aimed at developing bicyclic peptide inhibitors
of human plasma kallikrein (hPK) with high stability in the
intestinal environment for potential oral application. An in-
hibitor of hPK based on the Kunitz domain has been
approved in 2009 for the treatment of hereditary angioedema,
a life-threatening disease characterized by recurrent episodes
of severe swelling (angioedema) (Stolz and Horn, 2010). Due
to its large size and proteinous nature, the inhibitor requires
administration by injection. Smaller, peptidic inhibitors
based on bicyclic peptides were recently isolated from com-
binatorial libraries of bicyclic peptides and inhibit the
plasma protease with low- to sub-nanomolar affinities
(Heinis et al., 2009; Baeriswyl et al., 2012). Proteolytic sta-
bility measurements showed that the bicyclic peptides are
significantly more stable than linear peptides with identical
amino acid sequences (unpublished data). However, despite
their comparatively high proteolytic stability, we estimated
that the bicyclic inhibitors would not be sufficiently resistant
to the high protease activities in the intestinal environment
without excipients such as high concentrations of protease
inhibitors. The well-characterized bicyclic peptide inhibitor
of hPK inhibitor, PK15, has furthermore the handicap of
being cleaved by hPK between Arg7 and Asn8 upon binding
to the protease (Heinis et al., 2009). It is likely that the first
peptide ring of PK15 binds to hPK similar as a substrate
according to the so-called standard mechanism (Laskowski
and Qasim, 2000). Since pancreatic serine proteases such as
trypsin and chymotrypsin share high-sequence similarity
with hPK, PK15 (and other peptidic inhibitors binding
according to the standard mechanisms) might therefore have
a particularly high risk of being cleaved by the pancreatic
proteases.
Phage display technology combined with proteolytic pres-
sure has been applied to evolve proteins or peptides with
improved thermal and/or proteolytic stability. Kristensen and
Winter (1998) and independently Sieber et al. (1998) inserted
polypeptides between two domains of the minor coat protein
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p3 of filamentous phage to link protein stability with phage
infectivity. They showed that phage with less-stable proteins
were cleaved by proteases and lost their infectivity, while
phage containing stable, folded guest proteins were propa-
gated. This or similar proteolytic phage selection systems
(Finucane et al., 1999) were used to evolve the stability of
proteins such as RNase T1 (Sieber et al., 1998), barnase
(Pedersen et al., 2002) and RNase S (Chakravarty et al.,
2000) or to isolate folded protein domains from combinator-
ially shuffled polypeptide segments (Riechmann and Winter,
2000; Fischer et al., 2004; Riechmann and Winter, 2006).
In this work, we combined phage affinity selection and
proteolytic selection to develop bicyclic peptides with
improved stability toward intestinal proteases. We first
assessed the stability of filamentous phage toward pancreatin,
a mixture of the pancreatic digestive proteases found in the
intestinal lumen. Subsequently, we combined treatment of bi-
cyclic peptide phage libraries with pancreatin and affinity
selections with hPK and characterized the inhibitory activity
and proteolytic stability of isolated bicyclic peptides.
Results
Stability of bicyclic peptides toward intestinal proteases
The proteolytic stability of a previously generated bicyclic
peptide hPK inhibitor, PK15, was assessed by incubation
with different concentrations of pancreatin for 30 min at
378C and subsequent analysis by reversed phase high-
performance liquid chromatography (HPLC). Pancreatin is
an extract of porcine pancreatic glands and the main compo-
nent of the simulated intestinal fluid described in the US
Pharmacopedia (www.usp.org). The extract contains digest-
ive enzymes that are secreted into the lumen of the small in-
testine for protein breakdown. More than 50% of PK15 was
cleaved at pancreatin concentrations of 2.4 mg/ml (Fig. 1A).
At 10 mg/ml pancreatin, 90% of the inhibitor was digested
and at 20 mg/ml pancreatin or higher concentrations, 100%
PK15 was inactivated (Fig. 1A). Mass spectrometric analysis
of digested PK15 showed two degradation products with
masses that corresponded to bicyclic peptides in which Phe6
or the dipeptide Phe6-Arg7, respectively, were dissected fol-
lowing the cleavage of two amide bonds (Supplementary
Fig. S1). The cleavage sites are typical substrates of trypsin
(C-terminally to Arg5 and Arg7) and chymotrypsin
(C-terminally to Phe6) which are present in pancreatin at
high concentrations. For the generation of bicyclic peptide
inhibitors of hPK being more protease resistant than PK15,
we estimated that phage should be exposed to pancreatin
concentrations of 5 mg/ml or higher for 30 min at 378C.
Assessment of the stability of phage toward intestinal
proteases
Filamentous phage previously proofed resistant to high prote-
ase concentrations (Kristensen and Winter, 1998; Sieber
et al., 1998) but their resistance to the specific mixture of di-
gestive enzymes in pancreatin has not been assessed. As a
measure of the proteolytic resistance we determined the
number of phage able to infect bacteria after incubation with
different pancreatin concentrations. Wild-type phage
remained infective even at the highest pancreatin concentra-
tion tested (5 mg/ml; Fig. 1B). For phage selection of
bicyclic peptides, we preferred to use a phage mutant with a
disulfide-free p3, (Kather et al., 2005) to prevent potential
interference of the p3 cysteines with the cyclization reaction
involving the thiol-reactive tris-(bromomethyl)benzene
(TBMB). This phage mutant was less protease resistant but
remained infectious at pancreatin concentrations as high as
20 mg/ml (Fig. 1B). Since PK15 is slightly more susceptible
to pancreatin treatment, proteolytic phage selections were
feasible and we estimated suitable concentrations of pancrea-
tin to be between 5 and 20 mg/ml. The infectivity of bicyclic
peptide phage libraries was reduced at a similar extent as the
one of monoclonal disulfide-free phage not displaying a
peptide.
Phage selections
Phage affinity selections were combined with proteolytic
selections. Since bicyclic peptides with a smaller molecular
weight should have a better chance to cross the intestinal
Fig. 1. Effect of pancreatin activity on bicyclic peptide (A) and filamentous
phage (B). A window of pancreatin concentrations suited for proteolytic
phage display was assessed. The previously developed hPK bicyclic
inhibitor PK15 (open square) and filamentous phage (wild-type fd phage
(closed circle) and fd phage with cysteine-free p3 (Kather, Bippes and
Schmid, 2005) (closed triangle); 2  108 t.u.) were incubated for 30 min at
378C with various concentrations of pancreatin. The percentage of digested
PK15 was assessed by HPLC. The number of functional phage was
determined by measuring the infectivity. The hatched window indicates
pancreatin concentration suitable for proteolytic phage selection using the
disulfide-free phage (5–40 mg/ml).
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epithelium, we were particularly interested in improving the
proteolytic stability of those. Two phage libraries with bicyc-
lic peptides containing two rings of either three or four
random amino acids (library 3  3 and library 4  4) were
used (Fig. 2A). The libraries comprising 5.6  108 and 7.3  108
different peptide sequences, respectively, were produced by
chemically cyclizing linear peptides on phage with TBMB as
described before (Heinis et al., 2009). The two libraries were
joined and subjected to a first affinity selection with hPK.
Isolated phage were amplified and, prior to the second round
of affinity selection, treated for 30 min at 378C with 0 mg/ml
(control condition), 5, 10 or 20 mg/ml pancreatin. Titration
of isolated phage showed that fewer phage were captured
when treated with higher pancreatin concentrations (8.2  106,
8.3  102, 1.9  102 and 10 phage at 0, 5, 10 and 20 mg/ml
pancreatin). Sequencing of isolated peptides after two rounds
of phage panning performed without proteolytic pressure
revealed that the binders predominantly derived from the
3  3 library (28 out of the 29 sequenced clones) although
comparable numbers of phage from the 3  3 and 4  4 li-
braries were subjected to the selection (Fig. 2B). The pep-
tides showed a clear consensus sequence with an aromatic
amino acid in position 3, arginine in position 7 and valine or
alanine in position 8 (XCF/WXXCR
A/VXCX; Fig. 2B). When
proteolytic pressure was applied prior to the second round of
phage panning, this consensus sequence was also predomin-
antly found wherein the fraction of clones derived from the
4  4 library had increased (14 out of the 65 sequenced
clones; Fig. 2B).
Inhibitory activity and proteolytic stability of isolated
bicyclic peptides
Peptides of four clones isolated without and five with proteo-
lytic pressure (10 or 20 mg/ml pancreatin) were chemically
synthesized with a free N-terminus and an amidated
C-terminus, cyclized with TBMB and their inhibitory activ-
ity determined. The bicyclic peptides inhibited hPK with
IC50s ranging from 7.5 to 450 nM (Fig. 2B, Table I). In in-
hibitory assays, performed in biological triplicates, the four
bicyclic peptides (PK407, PK408, PK411 and PK417) iso-
lated without pancreatin pressure showed on average 68-fold
and 159-fold increased IC50s when treated for 30 min at
378C with 10 mg/ml and 20 mg/ml pancreatin, respectively
(Fig. 3A, Table I). In contrast, three of the five peptides iso-
lated under pancreatin pressure (PK459, PK472 and PK474)
presented significantly smaller losses in inhibitory activity
when treated with 10 and 20 mg/ml pancreatin, their IC50s in-
creasing on average 2-, 2- and 3-fold and 7-, 6- and 15-fold,
respectively (Fig. 3A, Table I). We next assessed by HPLC
the protease resistance of the three bicyclic inhibitors having
shown an improved stability in the inhibition assay (PK459,
PK472 and PK474) versus three bicyclic inhibitors isolated
without proteolytic pressure (PK407, PK408 and PK411).
The percentage of non-digested peptide remaining after in
vitro digestion with the various concentrations of pancreatin
(10 and 20 mg/ml) was determined by measuring the area
under the peaks in the HPLC chromatograms (Fig. 3B).
When treated with 20 mg/ml pancreatin, inhibitors selected
without proteolytic pressure were almost completely digested
(in average ,2% undigested inhibitor remaining) whereas
the fractions of intact bicyclic peptide of the protease
resistant group were in average 16, 20 and 9%, respectively
(Fig. 3C).
Proline in position 5 increases proteolytic stability
Sequence comparison of bicyclic peptides displaying a
higher stability toward pancreatin revealed the presence of a
proline residue in position 5 (PK459, PK472 and PK474),
which is not found in all the bicyclic peptides that proved
more prone to pancreatic digestion (PK407, PK408, PK411,
PK417, PK456 and PK473; Fig. 2B). This observation sug-
gested that the presence of a proline in this specific position
might increase the proteolytic stability. To assess the poten-
tial finding of such a ‘protective mark’, three protease-
susceptible peptides (PK407, PK408 and PK411) were
synthesized with a proline in position 5 (PK407-Pro,
PK408-Pro and PK411-Pro; Fig. 4A). After cyclization, their
resistance to proteolytic degradation was compared with the
proline-free counterparts by measuring the IC50s of all six bi-
cyclic peptides pre- and post-in vitro digestion. As shown in
Fig. 4A, the introduction of a proline in position 5 did not
significantly affect the inhibitory activity pre-in vitro diges-
tion. When treated with pancreatin, the bicyclic peptides
with proline showed a much smaller reduction in inhibitory
activity than their proline-free counterparts (Fig. 4B). The re-
sidual inhibitory activity following pancreatin treatment is
compared for all the bicyclic peptides in Fig. 4C.
Stability in intestinal fluid
To gain an idea of the stability of the evolved bicyclic pep-
tides in an intestinal environment, we incubated the most
stable bicyclic peptide (PK411-Pro, 100 mg/ml) in various
dilutions of mouse intestinal fluid (MIF, isolated from the
small intestine of 2–3 mice) and quantified the remaining
fraction of intact inhibitor by HPLC. Incubation of
PK411-Pro at 378C for 30 min in 500-fold diluted MIF led
to a similar extent of degradation as incubation with 20 mg/
ml pancreatin (between 35 and 40% of undigested bicyclic
peptide) (Fig. 5, right panels). As expected, the bicyclic
peptide PK411 without the proline residue was completely
degraded at the same conditions (Fig. 5, left panels). The sta-
bility was much dependent on the concentration of bicyclic
peptide in the assay. When the peptide was incubated at a
20-fold higher concentration (2 mg/ml), 10% of the bicyclic
peptide PK411-Pro remained intact in 50-fold diluted MIF.
Analysis by reversed-phase HPLC showed that the degrad-
ation products had similar retention times as those formed by
pancreatin, suggesting similar enzymatic activities in the two
extracts and that pancreatin is suitable to simulate the intes-
tinal proteolytic activities.
Discussion
We have shown that bicyclic peptide antagonists with
improved stability can be isolated from phage libraries by
combined affinity and proteolytic selection. In a first set of
experiments, we have assessed the stability of filamentous
phage toward the pancreatic proteases found in the intestinal
environment. While wild-type phage was completely stable
toward high pancreatin concentrations, a mutant phage which
we preferentially use for the screening of bicyclic peptide li-
braries was less resistant but stable enough to evolve bicyclic
peptide inhibitors of hPK with improved stability compared
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with the previously developed inhibitor PK15. To improve
further the stability of the bicyclic peptide hPK inhibitors,
we estimate that the herein applied phage with disulfide-free
p3 is not sufficiently resistant to proteases. However, it might
be possible to improve the stability of the mutant phage
toward intestinal proteases by directed evolution, similarly as
Schmid and co-workers had improved the stability of fila-
mentous phage to high temperatures and chymostrypsin
(Martin and Schmid, 2003; Kather et al., 2005).
Three out of five bicyclic peptides isolated under proteo-
lytic pressure were significantly more stable toward pancreat-
ic proteases than all those selected without proteolytic
pressure. For all bicyclic peptides, the residual inhibitory
activity correlated well with the degree of degradation
observed in the HPLC chromatograms. Only a small number
of discrete degradation products were seen in the chromato-
grams indicating that the bicyclic peptides were cleaved at a
few specific sites. Most likely the products are generated by
trypsin and chymotrypsin which dominate the proteolytic ac-
tivity in the intestine and cleave preferentially after lysine or
arginine and large hydrophobic amino acids, respectively.
In reversed-phase HPLC, all degradation products eluted at a
more polar solvent which is expected as cleavage of a
peptide loop generates new N-termini and hence additional
charged groups. The bicyclic peptides with improved stabil-
ity showed digestion products with similar retention times in
Fig. 2. Peptide library format and peptide sequences isolated with or without proteolytic pressure. (A) Format of phage peptide libraries 3  3 and 4  4. ‘X’
represents any of the 20 natural amino acids and ‘C’ a cysteine residue. (B) Peptide sequences isolated after the second round of phage panning for the four
different experimental conditions: 0 mg/ml (control), 5, 10 and 20 mg/ml pancreatin. Amino acid similarities are highlighted in color (Rasmol color code). Nine
bicyclic peptides were chemically synthesized and their inhibitory activity (IC50) is indicated.
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the HPLC chromatograms but the cleavage occurred at sig-
nificantly higher pancreatin concentrations.
An interesting observation was that all the three bicyclic
peptides with improved stability contained a proline residue
in the same amino acid position. It is known that pancreatic
proteases such as trypsin or chymotrypsin do not efficiently
cleave Xaa-Pro amide bonds. This protection mechanism
may apply for the bicyclic peptide PK459 in which the
trypsin substrate lysine is followed by the proline but likely
not for the other two biyclic peptides (PK472 and PK474).
In these peptides, the proline may constrain the conformation
of the first peptide loop (or indirectly the second one)
through its locked f dihedral angle. To confirm the role of
proline as a ‘protective mark’, we introduced proline into
three bicyclic peptides that showed low stability. The
mutants indeed showed a higher stability wherein the im-
provement was in the same range as the one of the phage
selected clones. Analysis of the cleavage sites in the bicyclic
peptides might help understanding better the role of proline
in stabilizing the macrocycles.
Finally, we assessed the stability of the most stable bicyc-
lic peptide in intestinal fluid of mice which showed that at
the lower concentration tested (100 mg/ml), 36% of the bi-
cyclic peptide resisted 500-fold diluted intestinal fluid at
378C for 30 min. If applied at higher concentration (2 mg/ml),
the bicyclic peptide was significantly more resistant, namely
10% resisted a 50-fold diluted intestinal fluid. Therefore, a
higher dosage of this potent inhibitor should significantly
help increasing its oral bioavailability. The higher stability of
the peptide macrocycle evolved in this work should allow
the use of milder excipients such as lower concentrations of
protease inhibitors, interfering less with the natural gastro-
intestinal activity.
In conclusion, we show that implementing pancreatic di-
gestion pressure in phage affinity selections is an attractive
avenue to enrich peptide macrocycles with higher stability in
intestinal fluid. The approach allowed us to further improve
the stability of already relatively stable bicyclic peptide inhi-
bitors which is an important step toward the development of
an orally available hPK antagonist.
Material and methods
Cloning of phage libraries
The library 3  3 was cloned as follows. The genes encoding
semi-random peptides with the sequence Xaa-Cys-(Xaa)3-Cys-
(Xaa)3-Cys-Xaa, the linker Ser-His-Ser and the two disulfide-
free domains D1 and D2 were cloned in the correct orientation
into the phage vector 21tet(5). The vector is based on the
phage vector fdg3p0ss21 (Kather et al., 2005) and contains a
2.5 kb stuffer fragment instead of the gene region coding for
the D1 and D2 domains of phage p3. The vector was cloned by
ligating two SfiI-digested DNA fragments obtained in two sep-
arate polymerase chain reaction (PCR). In the first PCR reac-
tion, nearly the whole vector fdg3p0ss21 (excluding the genes
coding D1 and D2) was amplified with the primers g3pNba
(CAGTCAGGCCTCGGGGGCCATGGCTTCTGGTACCCCGGT-
TAAC) and pelbsfifo (GACTGAGGCCGGCTGGGCCGCATA-
GAAAGGAACAACTAAAGGAAT). In the second PCR reaction,
the tetracycline resistance gene from the vector fd-tet-DOG1
(Hoogenboom et al., 1991) was amplified with the primers
tetsfiba (CAGTCAGGCCCAGCCGGCCGATCTCGGGAA-
AAGCGTTGGTCAC) and tetsfifo (GACTGAGGCCCCCGA-
GGCCTTCCCTTTGTCAACAGCAATGG). The ligated DNA
was transformed into TG1 cells. The genes encoding the peptide
repertoire and the two p3 domains were created in a PCR reaction




using the vector fdg3p0ss21 as a template. 11 mg of
SfiI-digested PCR product and 55 mg SfiI-digested 21tet(5)
vector were ligated and electroporated into TG1 cells. The
transformed cells were incubated for 1 h in 2YT media at 378C
and plated on seven large (20 cm diameter) chloramphenicol
(30 mg/ml) 2YT plates. Colonies were scraped off the plates
with 2YT media, supplemented with 10% glycerol and stored
at 2808C. The library 4  4 was cloned as follows. The genes
encoding semi-random peptides with the sequence
Xaa-Cys-(Xaa)4-Cys-(Xaa)4-Cys-Xaa, the linker Ser-His-Ser
and the two disulfide-free domains D1 and D2 were cloned in
the correct orientation into the phage vector fd0ssD12 (Heinis
et al., 2009). The genes encoding the peptide repertoire and
the two p3 domains were created in a PCR reaction with the




ACAGG-30) using the vector fdg3p0ss21 as a template.
13.5 mg of SfiI-digested PCR product and 67 mg SfiI-digested
fd0ssD12 vector were ligated and electroporated into TG1
cells. The transformed cells were incubated for 1 h in 2YT
media at 378C and plated on seven large (20 cm diameter)
chloramphenicol (30 mg/ml) 2YT plates. Colonies were
scraped off the plates with 2YT media, supplemented with
10% glycerol and stored at 2808C.
Phage selections combined with in vitro digestion
Glycerol stocks of phage libraries (library 3  3 and library
4  4) were each diluted to OD600 ¼ 0.1 in 1.5 l 2YT/chlor-
amphenicol (30 mg/ml) cultures and phage were expressed at
308C overnight (15–16 h). Phage from both libraries were
purified, chemically modified as described in Heinis et al.
Table I. IC50s of bicyclic peptide plasma kallikrein inhibitors measured












PK407 7.5+3.2 1117+407 2283+226
PK408 10.6+0.5 720+80 1583+486
PK411 112.7+22.1 1900+507 15600+5973




PK456 115.7+24 10 193+3687 .20 000
PK459 158.7+25.7 347+98 1120+250
PK472 18.2+4.2 39+3 101+32
PK473 178.3+12.6 11 733+1617 19 600+693
PK474 51.7+10.4 178+12 793+78
Rationally
designed
PK407-Pro 17.7+7.5 48+14 347+23
PK408-Pro 27.3+9.5 88+26 390+61
PK411-Pro 64+16.1 96+14 158+29
The assay was performed in biological triplicates. The average and standard
deviation are indicated.
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(2009) and pooled in a 1 : 1 mixture. Biotinylated hPK
(3 mg; Innovative Research, Novi, MI, USA) was incubated
with 50 ml pre-washed magnetic streptavidin beads (Dynal,
M-280 from Life Technologies, Carlsbad, CA, USA) for
10 min at room temperature. Beads were washed three times
prior to blocking with 0.5 ml buffer A (10 mM Tris-Cl, pH
7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM CaCl2) containing
1% bovine serum albumin (BSA) and 0.1% Tween 20 for
30 min at room temperature with rotation. Chemically modi-
fied phage (typically 1010–1011 t.u. dissolved in 2 ml buffer
A) were concomitantly blocked by addition of 1 ml buffer
A containing 3% BSA and 0.3% Tween 20. Blocked bead
conjugates were then mixed with the blocked phage and
incubated for 30 min on a rotating wheel at room tempera-
ture. Beads were washed eight times with buffer A contain-
ing 0.1% Tween 20 and twice with buffer A before
incubation with 100 ml of 50 mM glycine, pH 2.2 for 5 min.
Eluted phage were transferred to 50 ml of 1 M Tris-Cl, pH 8
for neutralization, incubated with 30 ml TG1 cells at
OD600 ¼ 0.4 for 90 min at 378C and the cells were plated on
large 2YT/chloramphenicol plates. Bacteria were collected
and cultured in 1 l 2YT/chloramphenicol (30 mg/ml) media
for phage production as described above. After purification
and chemical modification, the phage were incubated for
30 min at 378C with four different pancreatin (Sigma
Aldrich, St Louis, MO, USA) concentrations: 0 mg/ml
(control), 5, 10 and 20 mg/ml in 50 mM KH2PO4, pH 7.4.
Buffer exchange was performed post-in vitro digestion
(3000 pancreatin dilution) by concentrating the reaction in
a centrifugation filter (Vivaspin 20, 10 MWCO; Sartorius,
Go¨ttingen, Germany) and dilution with buffer A. A second
round of panning was performed using the same selection
procedures but neutravidin-coated magnetic beads to prevent
the enrichment of streptavidin-specific peptides. The neutra-
vidin beads were prepared by reacting 0.8 mg neutravidin
(Pierce, Rockford, IL, USA) with 0.5 ml tosyl-activated mag-
netic beads (Dynal, M-280 from Life Technologies) accord-
ing to the supplier’s instructions.
Fig. 3. Proteolytic stability of selected bicyclic peptides. (A) Inhibitory activity pre- and post-in vitro digestion with 10 and 20 mg/ml pancreatin. In contrast to
the peptides selected without proteolytic pressure (PK407, PK408, PK411 and PK417), three out of five peptides selected with proteolytic pressure (PK459,
PK472 and PK474) presented significantly smaller losses in inhibitory activity upon in vitro digestion, revealing their increased resistance to proteolytic
degradation. (B) Proteolytic resistance assessment by HPLC. HPLC chromatograms pre- and post-in vitro digestion with 10 and 20 mg/ml pancreatin of three
peptides selected without proteolytic pressure (PK407, PK408 and PK411) versus the three peptides having shown an improved stability in the inhibition assay
(PK459, PK472 and PK474). The peak corresponding to the non-digested peptide is highlighted by an arrow. Data from one representative experiment are
shown. (C) Quantification of the percentage residual peptide post-in vitro digestion. The in vitro digestion assays were performed in biological triplicates.




Fmoc-protected amino acids were purchased from Bachem
(Bubendorf, Switzerland) or GL Biochem (Shanghai, China).
Rink Amide AM resin (200–400 mesh, loading 0.36 mmol/g),
O-Benzotriazole-N,N,N0,N0-tetramethyl-uronium-hexafluoro-
phosphate (HBTU) and N-ethyldiisopropylamine (DIEA)
were purchased from Iris Biotech (Marktredwitz, Germany).
Piperidine, trifluoroacetic acid (TFA) and 1,2-ethanedithiol
(EDT) were used as received from Sigma Aldrich.
Acetonitrile (ACN) was purchased from Thermo Fisher
Scientific (Waltham, MA, USA). The peptides were pre-
pared by solid-phase peptide synthesis on an Advanced
ChemTech 348 V peptide synthesizer (Aapptec, Louisville,
USA), by standard 9-fluorenylmethoxycarbonyl (Fmoc)
group chemistry protocols and Rink Amide AM resin
support (0.1 mmol scale). Fmoc groups were removed using
2.5 ml of a 20% (v/v) solution of piperidine in dimethylform-
amide (DMF) and amino acid coupling was carried out
following a double-coupling strategy with a 6-fold excess of
Fmoc-amino acids (0.2 M in DMF). Coupling was achieved
using a 1/0.9/2 ratio of amino acid/HBTU/DIEA in DMF.
The deprotection and coupling times were 5 and 30 min, re-
spectively. Five times 3 ml DMF washes were performed
after deprotection and coupling steps. The peptide-loaded
resin was treated with a 90/2.5/2.5/2.5/2.5 (v/v) mixture of
TFA/thioanisole/water/phenol/EDT for 3 h, which simultan-
eously cleaved the peptide from the resin and removed all
side-chain protective groups. The cleaved peptides were sub-
sequently isolated by precipitation in cold diethyl ether fol-
lowed by centrifugation. The precipitated peptides were
resuspended in diethyl ether and centrifuged (three times).
Finally, the peptides were dissolved in a solution of 50 : 50
ACN: MilliQ water and lyophilized. The synthetic peptides
were dissolved in aqueous buffer (20 mM NH4HCO3, 5 mM
ethylenediaminetetra-acetate (EDTA), pH 8.0) at a concentra-
tion of 0.5 mM and TBMB dissolved in ACN was added to
obtain the following final concentrations: 80% aqueous
buffer (20 mM NH4HCO3, 5 mM EDTA, pH 8.0, degased),
20% ACN, 0.5 mM peptide and 1 mM TBMB. The reaction
solutions were kept in a 308C water bath for 1 h.
The product was purified by reversed-phase HPLC
(XBridge BEH300 Prep C18 column; Waters, Milford, MA,
USA) on a Waters Prep LC 4000 system with a 99.9% H2O/
0.1% TFA:99.9% ACN/0.1% TFA linear gradient from 0 to
50% over 30 min at a flow rate of 6 ml/min. The composition
of the peptide was confirmed by electrospray ionization
mass spectrometry (TSQ7000, Thermo Fisher Scientific).
The purified peptides were freeze dried.
In vitro digestion assay
In vitro digestion assay using pancreatin: 10 mg of peptide
was incubated with different pancreatin concentrations (0, 10
and 20 mg/ml) in 100 ml of 50 mM KH2PO4, pH 7.4 for
30 min at 378C. Pancreatin was inactivated post-incubation
Fig. 4. Effect of proline in position 5 on the proteolytic stability. (A) Three
bicyclic peptides without improved proteolytic stability (PK407, PK408 and
PK411) were re-synthesized with a proline in position 5 and their IC50s
determined. (B) Inhibitory activities of PK407-Pro, PK408-Pro and
PK411-Pro pre- and post-treatment with 10 or 20 mg/ml pancreatin. The
bicyclic peptides with proline showed a substantially smaller reduction in
inhibitory activity upon in vitro digestion compared with their proline-free
counterparts, confirming the protective benefit of a proline in position 5.
In vitro digestion assays were performed in biological triplicates. Medium
values and the corresponding standard deviations are indicated. (C)
Quantification of the residual inhibitory activity post-in vitro digestion. The
extent of inhibition (% enzymatic activity blocked) was measured at an
inhibitor concentration equalling the IC50 of each bicyclic peptide.
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either by heat inactivation (10 min at 1008C) or by acidic pH
(0.5% TFA). Assays were performed in biological triplicates.
In vitro digestion assay using mouse intestinal fluid:
100 mg or 2 mg of peptide were incubated for 30 min at
378C with various dilution of mouse intestinal fluid.
Enzymatic activity was stopped post-incubation by acidic pH
(0.5% TFA). Fresh mouse intestinal content was extracted
from the small intestine of 2–3 mice, pooled and before use
diluted with 50 mM KH2PO4, pH 7.4.
Inhibition assay
Residual hPK activity was measured in buffer containing
10 mM Tris-Cl, pH 7.4, 150 mM NaCl, 10 mM MgCl2,
1 mM CaCl2, 0.1% w/v BSA, 0.01% v/v Triton-X100 and
5% v/v dimethyl sulfoxide in a volume of 150 ml. Final con-
centration of hPK was 0.75 nM. Four-fold dilutions of inhibi-
tors were prepared ranging from 20 mM to 1.2 nM. For the
determination of the IC50 inhibitory constants, the
Z-Phe-Arg-AMC fluorogenic substrate (Bachem) was used at
a final concentration of 50 mM. Fluorescence intensity was
measured with a Spectramax Gemini fluorescence plate
reader (excitation at 355 nm, emission at 460 nm; Molecular
Devices, Sunnyvale, CA, USA). The reactions were per-
formed at 258C. IC50 values were determined using the
Softmax Pro 3.1 software. Fitting curves were generated
using Matlab software (MathWorks, Natick, MA, USA).
HPLC
Pre- and post-in vitro digestion samples were analyzed by
reversed-phase HPLC (Zorbax, analytical C18 column;
Agilent Technologies, Santa Clara, CA, USA) on an Agilent
Technologies LC 1260 system with a 94.9% H2O/5% ACN/
0.1% TFA: 95% ACN/4.9% H2O/0.1% TFA linear gradient
from 0 to 100% over 20 min at a flow rate of 1 ml/min.
Peaks were integrated using the Agilent ChemStation soft-
ware. The percentage of non-digested peptide remaining
post-in vitro digestion was assessed by comparing the area
under the corresponding peak pre- and post-in vitro
digestion.
Supplementary data
Supplementary data are available at PEDS online.
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